Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Purity: ≥98%
CB-1158 analog (CB-1158, INCB01158 or Numidargistat analog) is a potent and orally bioavailable small-molecule inhibitor of the arginase with potential immunomodulating activities. Myeloid cells are an abundant leukocyte in many types of tumors and contribute to immune evasion. Expression of the enzyme arginase 1 (Arg1) is a defining feature of immunosuppressive myeloid cells and leads to depletion of L-arginine, a nutrient required for T cell and natural killer (NK) cell proliferation. CB-1158 has shown high anti-cancer activity in renal cell cancer, breast cancer, non-small cell lung cancer, acute myeloid leukemia, and other tumor types where arginase-secreting MDSCs are known to play an immunosuppressive role. Arginase blockade by CB-1158 may be an effective therapy in multiple types of cancer, also the combination of CB-1158 with standard-of-care chemotherapy or other immunotherapies that target T-cell activation, such as CTLA-4 and PD-1 antibodies may yield improved clinical responses. CB-1158 is currently in a Phase I clinical trial as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
ln Vitro |
|
||
---|---|---|---|
ln Vivo |
|
||
Animal Protocol |
|
||
References |
J Immunother Cancer.2017 Dec 19;5(1):101;WO 2017075363 A1.
|
Molecular Formula |
C18H27BCL2N2O4
|
|
---|---|---|
Molecular Weight |
417.13
|
|
Exact Mass |
416.144
|
|
CAS # |
1345810-21-0
|
|
Related CAS # |
2095732-06-0 ;1345810-21-0;
|
|
PubChem CID |
66832679
|
|
Appearance |
Typically exists as solid at room temperature
|
|
Hydrogen Bond Donor Count |
4
|
|
Hydrogen Bond Acceptor Count |
6
|
|
Rotatable Bond Count |
9
|
|
Heavy Atom Count |
27
|
|
Complexity |
480
|
|
Defined Atom Stereocenter Count |
0
|
|
InChi Key |
ISYBHIALKUAHGV-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C18H27BCl2N2O4/c20-15-4-3-13(16(21)11-15)12-23-9-5-14(6-10-23)18(22,17(24)25)7-1-2-8-19(26)27/h3-4,11,14,26-27H,1-2,5-10,12,22H2,(H,24,25)
|
|
Chemical Name |
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3973 mL | 11.9867 mL | 23.9733 mL | |
5 mM | 0.4795 mL | 2.3973 mL | 4.7947 mL | |
10 mM | 0.2397 mL | 1.1987 mL | 2.3973 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Inhibition of arginase reverses myeloid cell-mediated suppression of in vitro T cell proliferation.J Immunother Cancer.2017 Dec 19;5(1):101. th> |
---|
CB-1158 has favorable pharmacokinetic and pharmacodynamic properties in vivo with no overt signs of toxicity.J Immunother Cancer.2017 Dec 19;5(1):101. td> |
Arginase inhibition reduces tumor growth in vivo. td> |
CB-1158 requires an intact immune system for efficacy.J Immunother Cancer.2017 Dec 19;5(1):101. th> |
---|
CB-1158-treated animals have increased tumor-infiltrating cytotoxic cells and decreased myeloid cells.J Immunother Cancer.2017 Dec 19;5(1):101. td> |
CB-1158 combines with immune checkpoint blockade, T cell transfer, or NK cell transfer to inhibit tumor growth.J Immunother Cancer.2017 Dec 19;5(1):101. td> |
CB-1158 combines with gemcitabine to inhibit tumor growth.J Immunother Cancer.2017 Dec 19;5(1):101. th> |
---|
Arginase 1 is abundant in multiple types of cancer.J Immunother Cancer.2017 Dec 19;5(1):101. td> |